Given that antigen-specific inhibitory CD8+ Tregs could be useful as potential immunotherapeutic tools in the context of autoimmune diseases, it remains to be demonstrated whether CII protein will drive similar in vivo immuno-regulatory responses when tested in the context of an autoimmune disease animal model. The gene discussed is CD8A; the disease is autoimmune disease.